Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at B. Riley

B. Riley reaffirmed their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note published on Wednesday,Benzinga reports. B. Riley currently has a $24.00 price target on the stock, up from their prior price target of $21.00. B. Riley also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.06 EPS, Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.14 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.44 EPS, FY2026 earnings at $1.08 EPS, FY2027 earnings at $1.45 EPS, FY2028 earnings at $1.66 EPS and FY2029 earnings at $1.82 EPS.

A number of other analysts have also recently commented on ETON. Craig Hallum upped their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a research note on Wednesday.

Eton Pharmaceuticals Stock Down 3.8 %

Shares of NASDAQ ETON opened at $14.22 on Wednesday. The firm’s 50-day moving average price is $15.58 and its 200-day moving average price is $11.54. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $18.41. The company has a market cap of $370.45 million, a PE ratio of -64.64 and a beta of 1.37.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). The business had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. As a group, equities research analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ETON. Mink Brook Asset Management LLC purchased a new stake in Eton Pharmaceuticals in the fourth quarter worth about $6,071,000. Cannell Capital LLC bought a new position in shares of Eton Pharmaceuticals during the 4th quarter valued at approximately $5,079,000. Wasatch Advisors LP purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth approximately $1,431,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Eton Pharmaceuticals by 230.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock worth $2,862,000 after acquiring an additional 149,864 shares during the period. Finally, Millennium Management LLC bought a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $1,850,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.